Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.80+0.22 (+1.62%)
Close on Nov 20, 2026Market cap $338.17MP/E –Yield –
Lyell Immunopharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Lyell Immunopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$133.97M. For fiscal 2025 it was -$150.80M. The highest annual figure on record is $23.43M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$150.80M | – |
| FY2024 | Dec 31, 2024 | -$162.86M | – |
| FY2023 | Dec 31, 2023 | -$166.38M | – |
| FY2022 | Dec 31, 2022 | -$193.83M | – |
| FY2021 | Dec 31, 2021 | -$191.75M | – |
| FY2020 | Dec 31, 2020 | -$212.36M | -1006.5% |
| FY2019 | Dec 31, 2019 | $23.43M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$34.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$32.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.64M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.63M | – |
| Q1 FY2025 | Mar 31, 2025 | -$54.98M | – |
| Q4 FY2024 | Dec 31, 2024 | -$47.29M | – |
| Q3 FY2024 | Sep 30, 2024 | -$35.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.43M | – |
| Q1 FY2024 | Mar 31, 2024 | -$42.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$40.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$37.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$40.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$44.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$39.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$51.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$57.59M | – |
| Q4 FY2021 | Dec 31, 2021 | -$43.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$37.09M | – |
| Q2 FY2021 | Jun 30, 2021 | -$58.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$52.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$51.61M | – |
| Q3 FY2020 | Sep 30, 2020 | -$34.27M | – |
See a number that looks wrong?